Cargando…

PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy

PURPOSE: There remain a lack of biomarkers for endocrine therapy resistance in patients with breast cancer (BC), which is proving to be a great challenge. In vitro experiments have shown that downregulation of PTEN expression leads to resistance to tamoxifen (TAM) in BC cells. We aimed to investigat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Yu, Xie, Guiqin, Wang, Zhu, Wang, Yu, Wang, Yanping, Zheng, Hong, Zhong, Xiaorong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Preclinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841328/ https://www.ncbi.nlm.nih.gov/pubmed/34978016 http://dx.doi.org/10.1007/s10549-021-06463-6

Ejemplares similares

MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy
por: Zhong, XiaoRong, et al.
Publicado: (2016)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis
por: Engels, C. C., et al.
Publicado: (2015)

A prospective cohort study of clinical characteristics and outcomes in Chinese patients with estrogen receptor-negative/progesterone receptor-positive early breast cancer
por: Fan, Yu, et al.
Publicado: (2023)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Integrative prognostic analysis of tumor–infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy
por: Yazaki, Shu, et al.
Publicado: (2022)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
por: Hilborn, Erik, et al.
Publicado: (2014)

Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells
por: Kim, Seung-Su, et al.
Publicado: (2020)

Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells
por: Leung, Euphemia, et al.
Publicado: (2011)

Adipose PTEN acts as a downstream mediator of a brain-fat axis in environmental enrichment
por: Huang, Wei, et al.
Publicado: (2020)

Nucleolar protein 10 (NOP10) predicts poor prognosis in invasive breast cancer
por: Elsharawy, Khloud A., et al.
Publicado: (2020)

Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy
por: Al-Subhi, Nouf, et al.
Publicado: (2018)

High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
por: Jansen, M. P. H. M., et al.
Publicado: (2011)

KIF20A is a Prognostic Marker for Female Patients with Estrogen Receptor-Positive Breast Cancer and Receiving Tamoxifen as Adjuvant Endocrine Therapy
por: Huang, Xuchen, et al.
Publicado: (2023)

Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
por: Uchino, J., et al.
Publicado: (1994)

Patterns of biomarker expression in patients treated with primary endocrine therapy – a unique insight using core needle biopsy tissue microarray
por: Parks, R. M., et al.
Publicado: (2020)

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2021)

The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer
por: Eustace, A. J., et al.
Publicado: (2021)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani, Dimple, et al.
Publicado: (2021)

SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment
por: Huang, Yu-Hsiang, et al.
Publicado: (2018)

Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer
por: Bhardwaj, Anjana, et al.
Publicado: (2021)

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
por: Andreano, Kaitlyn J., et al.
Publicado: (2020)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China
por: Liu, Xiaoran, et al.
Publicado: (2021)

Influence of GSTP-1 Polymorphism on the Prognosis of Patients with High-Grade Glioma Who Received Temozolomide Plus Radiotherapy Adjuvant Treatment
por: Zhi, De-Bao, et al.
Publicado: (2021)

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
por: Perez, Edith A., et al.
Publicado: (2013)

Sex differences in binge‐like EtOH drinking, corticotropin‐releasing hormone and corticosterone: effects of β‐endorphin
por: Nentwig, Todd B., et al.
Publicado: (2018)

MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer
por: Han, Jinil, et al.
Publicado: (2017)

Investigating the role of endogenous estrogens, hormone replacement therapy, and blockade of estrogen receptor-α activity on breast metabolic signaling
por: Arnone, Alana A., et al.
Publicado: (2021)

Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer
por: Anderson, Richard A., et al.
Publicado: (2022)

Application of long non-coding RNA RBAT1 in improving diagnosis and prognosis of ovarian carcinoma
por: Luo, Jie, et al.
Publicado: (2022)

Photo‐mediated ultrasound therapy for the treatment of retinal neovascularization in rabbit eyes
por: Qin, Yu, et al.
Publicado: (2022)

Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients
por: Erber, Ramona, et al.
Publicado: (2020)

Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns
por: Bardowell, Sabrina A., et al.
Publicado: (2013)

Quantification of DNA Damage in Heart Tissue as a Novel Prediction Tool for Therapeutic Prognosis of Patients With Dilated Cardiomyopathy
por: Ko, Toshiyuki, et al.
Publicado: (2019)

DTX3 copy number increase in breast cancer: a study of associations to molecular subtype, proliferation and prognosis
por: Valla, Marit, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jppjeruk976m9lrg5m21j8n5cs